John McLauchlan

 

A6

Dr. John McLauchlan

John.McLauchlan@glasgow.ac.uk

Title of Presentation

HCV Research UK – Delivering Translational Research from a UK Cohort of Hepatitis C Virus-Infected Individuals

Date and Place

Session A2

 

Speaker Biography

Dr. John McLauchlan is the Associate Director of the MRC-University of Glasgow Centre for Virus Research and heads a research programme on hepatitis C virus (HCV). Since HCV Research UK was established in 2011, he has been co-chair of HCV Research UK along with Prof Will Irving, a clinical virologist at the University of Nottingham. HCV Research UK was set up by a consortium of clinicians and scientists with the specific aim of addressing fundamental clinical and scientific questions on HCV by making clinical data and samples available to the research community. Funding for the initiative came from the Medical Research Foundation through a grant of £1.92M. The consortium has recruited a cohort of >11,000 patients with HCV infection at 60 clinical centres across the UK, representing one of the largest HCV cohorts in the world. Clinical data and samples are held in a central database and biorepository respectively. HCV Research UK encourages applications for access to data and samples from within and outside of the UK through a process of evaluating proposed research studies; applications are given ethical approval and formal agreements are completed before data and samples are released. To date, there have been 65 approved applications that utilise the data and samples from HCV Research UK and the infrastructure now supports sub-studies for particular groups of patients. This includes a cohort of infected patients with a) severe liver disease who received novel antiviral therapy and b) cirrhosis for longitudinal studies. For long-term sustainability, HCV Research UK uses a model for cost recovery which will allow it to continue its work for at least the next 5 years.

 

Abstract

HCV Research UK was established in 2011 following an award of £1.92M from the Medical Research Foundation. The organisation was set up by a consortium of clinicians and scientists with the specific aim of addressing fundamental clinical and scientific questions on HCV by making clinical data and samples available to the research community. To achieve this aim, all data and samples were held in centralised databases and a biorepository. The consortium has recruited a cohort of >11,000 patients with HCV infection at 60 clinical centres across the UK, representing one of the largest HCV cohorts in the world. Since its inception, HCV Research UK has encouraged applications for access to data and samples from within and outside of the UK through a process of evaluating proposed research studies. In addition, the systems have been purposefully established and developed to allow flexibility for setting up sub-studies and customised data collection for specific projects. As a consequence, HCV Research UK has attracted and approved 65 applications that utilise the data and samples from the cohort. It also has studies that collect specific data and samples for niche cohort groups. Moreover, HCV Research UK uses a model for cost recovery which will allow it to continue its work for at least the next 5 years, this attaining long term sustainability.
The lecture will focus on the initial structure of HCV Research UK and how this has been adapted to fit the needs of users. Moreover, there will be a description of the data and sample types that have been collected and the challenges faced in acquiring information and material across a large clinical network. Finally, cost recovery for long term sustainability will be discussed with regard to our experience of raising funds to sustain the resource.